Antinociceptive effect of intrathecal neostigmine evaluated in rats by two different pain models.
The analgesic efficacy of cholinergic agonists and anticholinesterase agents has been widely recognized. The analgesic effect obtained by activating cholinergic mechanisms, however, seems to depend on the experimental pain model utilized for its evaluation. The antinociceptive effect of intraspinal neostigmine was examined in rats submitted concurrently to the tail flick and formalin tests. Neostigmine (8.25 and 16.5 nmol) produced a dose-dependent antinociceptive effect in the tail flick test (a model of phasic pain) and reduced the first phase (phasic pain) of the animal response to formalin also in a dose-dependent manner. The second phase (tonic pain) of the response to formalin, however, was slightly reduced after a longer period of time only by the higher dose of the anticholinesterase. The effect of neostigmine was not significantly different when the drug was injected into rats submitted exclusively to the tail flick test. The second phase of the animal response to formalin was slightly reduced by neostigmine (8.25 nmol) and strongly inhibited by the higher dose of the anticholinesterase when injection was made after the first phase. We conclude that phasic and tonic pain can both be controlled by high doses of neostigmine. In addition, we show that inhibition by a lower dose of neostigmine of the formalin-induced phasic pain did not prevent the subsequent occurrence of tonic pain produced by the irritant.
Prado
W A
WA
Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Brasil. wadprado@fmrp.usp.br
Gonçalves
A S
AS
D000818:Animals; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D007278:Injections, Spinal; D008297:Male; D009388:Neostigmine / Q000494:pharmacology*; D010147:Pain Measurement / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar
D002800:Cholinesterase Inhibitors; D009388:Neostigmine